D. N. Louis, A. Perry, and G. Reifenberger, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary, Acta Neuropathol, vol.131, issue.6, pp.803-820, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01479018

M. J. Riemenschneider, A. Perry, and G. Reifenberger, Histological classification and molecular genetics of meningiomas, Lancet Neurol, vol.5, issue.12, pp.1045-1054, 2006.

L. Rogers, M. Gilbert, and M. A. Vogelbaum, Intracranial meningiomas of atypical (WHO grade II) histology, J Neurooncol, vol.99, issue.3, pp.393-405, 2010.

F. Sahm, D. Schrimpf, and A. Olar, TERT Promoter mutations and risk of recurrence in meningioma, J Natl Cancer Inst, vol.108, issue.5, p.377, 2016.

F. Sahm, D. Schrimpf, and D. Stichel, DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis, Lancet Oncol, vol.18, issue.5, pp.682-694, 2017.

R. Goldbrunner, G. Minniti, and M. Preusser, EANO guidelines for the diagnosis and treatment of meningiomas, Lancet Oncol, vol.17, issue.9, pp.383-391, 2016.

M. Abedalthagafi, W. L. Bi, and A. A. Aizer, Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma, Neuro Oncol, vol.18, issue.5, pp.649-655, 2016.

P. K. Brastianos, P. M. Horowitz, and S. Santagata, Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations, Nat Genet, vol.45, issue.3, pp.285-289, 2013.

V. E. Clark, E. Z. Erson-omay, and A. Serin, Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO, Science, vol.339, issue.6123, pp.1077-1080, 2013.

D. E. Reuss, R. M. Piro, and D. T. Jones, Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations, Acta Neuropathol, vol.125, issue.3, pp.351-358, 2013.

N. L. Albert, M. Weller, and B. Suchorska, Response Assessment in Neuro-Oncology Working Group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas, Neuro Oncol, vol.18, issue.9, pp.1199-1208, 2016.

N. Galldiks, K. J. Langen, and W. B. Pope, From the clinician's point of viewwhat is the status quo of positron emission tomography in patients with brain tumors?, Neuro Oncol, vol.17, issue.11, pp.1434-1444, 2015.

C. N. Patel, A. R. Goldstone, F. U. Chowdhury, and A. F. Scarsbrook, FDG PET/CT in oncology: "raising the bar, Clin Radiol, vol.65, issue.7, pp.522-535, 2010.

J. W. Lee, K. W. Kang, and S. H. Park, 18F-FDG PET in the assessment of tumor grade and prediction of tumor recurrence in intracranial meningioma, Eur J Nucl Med Mol Imaging, vol.36, issue.10, pp.1574-1582, 2009.

D. Chiro, G. Hatazawa, J. Katz, D. A. Rizzoli, H. V. et al., Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and probability of recurrence: a PET study, Radiology, vol.164, issue.2, pp.521-526, 1987.

U. Cremerius, R. Bares, and J. Weis, Fasting improves discrimination of grade 1 and atypical or malignant meningioma in FDG-PET, J Nucl Med, vol.38, issue.1, pp.26-30, 1997.

D. Delbeke, C. Meyerowitz, and R. L. Lapidus, Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from highgrade brain tumors with PET, Radiology, vol.195, issue.1, pp.47-52, 1995.

R. S. Liu, C. P. Chang, and W. Y. Guo, 1-11C-acetate versus 18F-FDG PET in detection of meningioma and monitoring the effect of gamma-knife radiosurgery, J Nucl Med, vol.51, issue.6, pp.883-891, 2010.

A. Dutour, U. Kumar, and R. Panetta, Expression of somatostatin receptor subtypes in human brain tumors, Int J Cancer, vol.76, issue.5, pp.620-627, 1998.

J. C. Reubi, R. Maurer, and J. G. Klijn, High incidence of somatostatin receptors in human meningiomas: biochemical characterization, J Clin Endocrinol Metab, vol.63, issue.2, pp.433-438, 1986.

J. R. Menke, D. R. Raleigh, A. M. Gown, S. Thomas, A. Perry et al., Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen, Acta Neuropathol, vol.130, issue.3, pp.441-443, 2015.

C. B. Johnbeck, U. Knigge, and A. Kjaer, PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature, Future Oncol, vol.10, issue.14, pp.2259-2277, 2014.

W. Rachinger, V. M. Stoecklein, and N. A. Terpolilli, Increased 68Ga-DOTATATE uptake in PET imaging discriminates meningioma and tumor-free tissue, J Nucl Med, vol.56, issue.3, pp.347-353, 2015.

A. Afshar-oromieh, F. L. Giesel, and H. G. Linhart, Detection of cranial meningiomas: comparison of 68 Ga-DOTATOC PET/CT and contrast-enhanced MRI, Eur J Nucl Med Mol Imaging, vol.39, issue.9, pp.1409-1415, 2012.

M. Henze, J. Schuhmacher, and P. Hipp, PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas, J Nucl Med, vol.42, issue.7, pp.1053-1056, 2001.

M. L. Soto-montenegro, S. Peña-zalbidea, and J. M. Mateos-pérez, Meningiomas: a comparative study of 68Ga-DOTATOC, 68Ga-DOTANOC and 68Ga-DOTATATE for molecular imaging in mice, PLoS One, vol.9, issue.11, p.111624, 2014.

I. Virgolini, V. Ambrosini, and J. B. Bomanji, Procedure guidelines for PET/ CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE, Eur J Nucl Med Mol Imaging, vol.37, issue.10, pp.2004-2010, 2010.

N. L. Jansen, V. Graute, and L. Armbruster, MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?, Eur J Nucl Med Mol Imaging, vol.39, issue.6, pp.1021-1029, 2012.

A. Smits and B. G. Baumert, The clinical value of PET with amino acid tracers for gliomas WHO grade II, Int J Mol Imaging, p.372509, 2011.

N. Galldiks, G. Stoffels, and M. I. Ruge, Role of O-(2-18F-fluoroethyl)-Ltyrosine PET as a diagnostic tool for detection of malignant progression in patients with low-grade glioma, J Nucl Med, vol.54, issue.12, pp.2046-2054, 2013.

S. T. Astner, M. Dobrei-ciuchendea, and M. Essler, Effect of 11C-methionine-positron emission tomography on gross tumor volume delineation in stereotactic radiotherapy of skull base meningiomas, Int J Radiat Oncol Biol Phys, vol.72, issue.4, pp.1161-1167, 2008.

J. F. Cornelius, G. Stoffels, and C. Filß, Uptake and tracer kinetics of O-(2-(18)F-fluoroethyl)-L-tyrosine in meningiomas: preliminary results, Eur J Nucl Med Mol Imaging, vol.42, issue.3, pp.459-467, 2015.

J. K. Chung, Y. K. Kim, and S. K. Kim, Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo-or isometabolic on 18F-FDG PET, Eur J Nucl Med Mol Imaging, vol.29, issue.2, pp.176-182, 2002.

H. Arita, M. Kinoshita, and Y. Okita, Clinical characteristics of meningiomas assessed by 11 C-methionine and 18 F-fluorodeoxyglucose positronemission tomography, J Neurooncol, vol.107, issue.2, pp.379-386, 2012.

M. Sommerauer, J. K. Burkhardt, and K. Frontzek, 68Gallium-DOTATATE PET in meningioma: a reliable predictor of tumor growth rate?, Neuro Oncol, vol.18, issue.7, pp.1021-1027, 2016.

J. F. Cornelius, K. J. Langen, G. Stoffels, D. Hänggi, M. Sabel et al., Positron emission tomography imaging of meningioma in clinical practice: review of literature and future directions, Neurosurgery, vol.70, issue.4, pp.1033-1041, 2012.

S. Kawabata, R. Hiramatsu, T. Kuroiwa, K. Ono, and S. Miyatake, Boron neutron capture therapy for recurrent high-grade meningiomas, J Neurosurg, vol.119, issue.4, pp.837-844, 2013.

S. Miyatake, S. Kawabata, and N. Nonoguchi, Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas, Neuro Oncol, vol.11, issue.4, pp.430-436, 2009.

B. J. Krause, M. Souvatzoglou, and U. Treiber, Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates, Urol Oncol, vol.31, issue.4, pp.427-435, 2013.

T. Maurer, M. Eiber, M. Schwaiger, and J. E. Gschwend, Current use of PSMA-PET in prostate cancer management, Nat Rev Urol, vol.13, issue.4, pp.226-235, 2016.

G. Giovacchini, F. Fallanca, and C. Landoni, C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: an initial experience, Clin Nucl Med, vol.34, issue.1, pp.7-10, 2009.

N. Oyama, H. Ito, and N. Takahara, Diagnosis of complex renal cystic masses and solid renal lesions using PET imaging: comparison of 11C-acetate and 18F-FDG PET imaging, Clin Nucl Med, vol.39, issue.3, pp.208-214, 2014.

L. Huo, J. Guo, and Y. Dang, Kinetic analysis of dynamic (11)C-acetate PET/CT imaging as a potential method for differentiation of hepatocellular carcinoma and benign liver lesions, Theranostics, vol.5, issue.4, pp.371-377, 2015.

B. Mohsen, T. Giorgio, and Z. S. Rasoul, Application of C-11-acetate positron-emission tomography (PET) imaging in prostate cancer: systematic review and meta-analysis of the literature, BJU Int, vol.112, issue.8, pp.1062-1072, 2013.

N. Oyama, H. Akino, and H. Kanamaru, 11C-acetate PET imaging of prostate cancer, J Nucl Med, vol.43, issue.2, pp.181-186, 2002.

U. Tateishi, K. Tateishi, A. Hino-shishikura, I. Torii, T. Inoue et al., Multimodal approach to detect osseous involvement in meningioma: additional value of (18)F-fluoride PET/CT for conventional imaging, Radiology, vol.273, issue.2, pp.521-528, 2014.

U. Tateishi, K. Tateishi, and K. Shizukuishi, 18F-fluoride PET/CT allows detection of hyperostosis and osseous involvement in meningioma: initial experience, Clin Nucl Med, vol.38, issue.3, pp.125-131, 2013.

H. Chaves, Y. Bergamo, S. Paz, F. Sanchez, and S. Vazquez, Sphenoid wing meningioma behavior on 11C-PiB and 18F-FDG PET, Clin Nucl Med, vol.40, issue.1, pp.81-82, 2015.

R. Bilgin, N. Ergül, and T. F. Çermik, Incidental meningioma mimicking metastasis of prostate adenocarcinoma in 68Ga-labeled PSMA ligand PET/CT, Clin Nucl Med, vol.41, issue.12, pp.956-958, 2016.

I. U. Song, S. H. Lee, and Y. A. Chung, The incidental suggestive meningioma presenting as high 18F FP-CIT uptake on PET/CT study, Clin Nucl Med, vol.39, issue.1, pp.97-98, 2014.

I. R. Whittle, C. Smith, P. Navoo, and C. D. Meningiomas, Lancet, vol.363, issue.9420, pp.1535-1543, 2004.

M. D. Johnson, S. Z. Powell, P. J. Boyer, R. J. Weil, and P. L. Moots, Dural lesions mimicking meningiomas, Hum Pathol, vol.33, issue.12, pp.1211-1226, 2002.

A. Klingenstein, A. R. Haug, C. Miller, and C. Hintschich, Ga-68-DOTA-TATE PET/CT for discrimination of tumors of the optic pathway, Orbit, vol.34, issue.1, pp.16-22, 2015.

T. Iuchi, Y. Iwadate, and H. Namba, Glucose and methionine uptake and proliferative activity in meningiomas, Neurol Res, vol.21, issue.7, pp.640-644, 1999.

H. Ikeda, N. Tsuyuguchi, N. Kunihiro, K. Ishibashi, T. Goto et al., Analysis of progression and recurrence of meningioma using (11)C-methionine PET, Ann Nucl Med, vol.27, issue.8, pp.772-780, 2013.

S. Milker-zabel, Z. Bois, A. Henze, and M. , Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET, Int J Radiat Oncol Biol Phys, vol.65, issue.1, pp.222-227, 2006.

F. Nyuyki, M. Plotkin, and R. Graf, Potential impact of (68)Ga-DOTATOC PET/CT on stereotactic radiotherapy planning of meningiomas, Eur J Nucl Med Mol Imaging, vol.37, issue.2, pp.310-318, 2010.

I. Rutten, J. E. Cabay, and N. Withofs, PET/CT of skull base meningiomas using 2-18F-fluoro-L-tyrosine: initial report, J Nucl Med, vol.48, issue.5, pp.720-725, 2007.

A. L. Grosu, W. A. Weber, and S. T. Astner, 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy, Int J Radiat Oncol Biol Phys, vol.66, issue.2, pp.339-344, 2006.

L. Rogers, I. Barani, and M. Chamberlain, Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review, J Neurosurg, vol.122, issue.1, pp.4-23, 2015.

W. G. Kunz, L. M. Jungblut, and P. M. Kazmierczak, Improved detection of transosseous meningiomas using 68Ga-DOTATATE PET-CT compared to contrast-enhanced MRI, J Nucl Med, 2017.

N. A. Terpolilli, W. Rachinger, and M. Kunz, Orbit-associated tumors: navigation and control of resection using intraoperative computed tomography, J Neurosurg, vol.124, issue.5, pp.1319-1327, 2016.

A. L. Grosu, R. Lachner, and N. Wiedenmann, Validation of a method for automatic image fusion (BrainLAB System) of CT data and 11C-methionine-PET data for stereotactic radiotherapy using a LINAC: first clinical experience, Int J Radiat Oncol Biol Phys, vol.56, issue.5, pp.1450-1463, 2003.

B. Gehler, F. Paulsen, and M. O. Oksüz, DOTATOC-PET/CT for meningioma IMRT treatment planning, Radiat Oncol, vol.68, p.56, 2009.

R. Graf, F. Nyuyki, and I. G. Steffen, Contribution of 68Ga-DOTATOC PET/CT to target volume delineation of skull base meningiomas treated with stereotactic radiation therapy, Int J Radiat Oncol Biol Phys, vol.85, issue.1, pp.68-73, 2013.

O. Gudjonsson, E. Blomquist, A. Lilja, H. Ericson, M. Bergström et al., Evaluation of the effect of high-energy proton irradiation treatment on meningiomas by means of 11C-L-methionine PET, Eur J Nucl Med, vol.27, issue.12, pp.1793-1799, 2000.

M. Ryttlefors, T. Danfors, F. Latini, A. Montelius, E. Blomquist et al., Long-term evaluation of the effect of hypofractionated highenergy proton treatment of benign meningiomas by means of (11)C-Lmethionine positron emission tomography, Eur J Nucl Med Mol Imaging, vol.43, issue.8, pp.1432-1443, 2016.

K. L. Chatalic, D. J. Kwekkeboom, and M. De-jong, Radiopeptides for imaging and therapy: a radiant future, J Nucl Med, vol.56, issue.12, pp.1809-1812, 2015.

A. Otte, R. Herrmann, and A. Heppeler, Yttrium-90 DOTATOC: first clinical results, Eur J Nucl Med, vol.26, issue.11, pp.1439-1447, 1999.

M. Bartolomei, L. Bodei, D. Cicco, and C. , Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma, Eur J Nucl Med Mol Imaging, vol.36, issue.9, pp.1407-1416, 2009.

F. Minutoli, E. Amato, and A. Sindoni, Peptide receptor radionuclide therapy in patients with inoperable meningiomas: our experience and review of the literature, Cancer Biother Radiopharm, vol.29, issue.5, pp.193-199, 2014.

N. Marincek, P. Radojewski, and R. A. Dumont, Somatostatin receptortargeted radiopeptide therapy with 90Y-DOTATOC and 177Lu-DOTATOC in progressive meningioma: long-term results of a phase II clinical trial, J Nucl Med, vol.56, issue.2, pp.171-176, 2015.

K. Gerster-gilliéron, F. Forrer, H. Maecke, J. Mueller-brand, A. Merlo et al., 90Y-DOTATOC as a therapeutic option for complex recurrent or progressive meningiomas, J Nucl Med, vol.56, issue.11, pp.1748-1751, 2015.

M. C. Kreissl, H. Hänscheid, and M. Löhr, Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma, Radiat Oncol, vol.7, p.99, 2012.

A. Sabet, H. Ahmadzadehfar, U. Herrlinger, W. Wilinek, H. J. Biersack et al., Successful radiopeptide targeting of metastatic anaplastic meningioma: case report, Radiat Oncol, vol.6, p.94, 2011.

M. Van-essen, E. P. Krenning, and P. P. Kooij, Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma, J Nucl Med, vol.47, issue.10, pp.1599-1606, 2006.

K. Seystahl, V. Stoecklein, and U. Schüller, Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake, Neuro Oncol, vol.18, issue.11, pp.1538-1547, 2016.

C. Kratochwil, F. L. Giesel, and F. Bruchertseifer, ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience, Eur J Nucl Med Mol Imaging, vol.41, issue.11, pp.2106-2119, 2014.

T. Schumacher, S. Hofer, and K. Eichhorn, Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study, Eur J Nucl Med Mol Imaging, vol.29, issue.4, pp.486-493, 2002.